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Abstract
Background Percutaneous transhepatic gallbladder drainage (PTGBD) plays an important role in the treatment of elderly 
patients and/or patients in poor health with acute cholecystitis (AC). The primary aim of this study is to determine how 
these factors influence the clinical outcome of PTGBD. Moreover, we assessed the timing and results of subsequent 
cholecystectomies.
Patients and Methods We retrospectively examined the results of 162 patients undergoing PTGBD between 2010 and 2020 
(male–female ratio: 51.23% vs. 48.77%; mean age: 71.43 ± 13.22 years). Patient’s performance status and intervention out-
comes were assessed with clinical success rates (CSR) and in-hospital mortality. The conversion rate (CR) of possible urgent 
or delayed, elective laparoscopic cholecystectomies (LC) after PTGBD were analysed.
Results   PTGBD was the definitive treatment in 42.18% of patients, while it was a bridging therapy prior to cholecystectomy 
(CCY) for the other patients. CSR was 87.97%, it was only 64.29% in grade III AC. In 9.87% of the cases, urgent LC was 
necessary after PTGBD, and its conversion rate was approximately equal to that of elective LC (18.18 vs. 17.46%, respec-
tively, p = 0.2217). Overall, the post-PTGBD in-hospital mortality was 11.72%, while the same figure was 0% for grade I 
AC, 7.41% for grade II and 40.91% for grade III. Based on logistic regression analyses, in-hospital mortality (OR 6.07; CI 
1.79–20.56), clinical progression (OR 7.62; CI 2.64–22.05) and the need for emergency CCY (OR 14.75; CI 3.07–70.81) 
were mostly determined by AC severity grade.
Conclusion  PTGBD is an easy-to-perform intervention with promising clinical success rates in the treatment of acute chol-
ecystitis. After PTGBD, the level of gallbladder inflammation played a decisive role in the course of AC. In a severe, grade 
III inflammation, we have to consider low CSR and high mortality.
Keywords Acute cholecystitis · Laparoscopic cholecystectomy · Mortality · Conversion rate · Percutaneous 
cholecystostomy
Percutaneous transhepatic gallbladder drainage (PTGBD) is 
an invasive radiological method that has been used from the 
early 1980s [1–5], and it is now an essential part of treat-
ment for acute cholecystitis (AC). Ultrasound (US)-guided 
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PTGBD is a technically easy-to-perform method with a 
relatively high clinical success rate. According to the litera-
ture, the technical success rate of PTGBD is approximately 
95% during AC treatment, whereas the clinical success rate 
ranges between 56% and 100% [6–10].
Nowadays, the Tokyo Guidelines 2018 recommendations 
form the standard in treating AC [11]. Compared to the Tokyo 
Guidelines 2013 (TG13) [12], the 2018 (TG18) version further 
clarifies the role of PTGBD in treating AC. In grade II, mod-
erate AC urgent/early laparoscopic cholecystectomy (LC) is 
the primary therapy of choice. If the patient is unsuitable for 
surgery due to his general condition and/or does not respond 
adequately to antibiotics and general supportive care, PTGBD 
becomes necessary. According to the Tokyo Guidelines 2018, 
the indication for PTGBD in grade III AC is determined by 
the patient’s performance status (Charlson comorbidity index 
(CCI) [13], the American Society of Anesthesiologists (ASA) 
physical status [14]) based on negative predictive factors 
(jaundice and neurological and respiratory dysfunction) and 
favourable organ system failure (FOSF; cardiovascular and 
renal organ failure).
Complicated AC is a relatively high-mortality disease [15]. 
Emergency or early LC is a surgery with great technical dif-
ficulties, and it is accompanied by a high conversion rate [16, 
17], a chance of biliary duct injury and high mortality [8]. The 
aim of PTGBD is to provide an alternative treatment option 
to high-risk patients with moderate (grade II) or severe (grade 
III) AC. In some cases, when the patient is not even fit for 
elective surgery, PTGBD can provide a definitive therapeutic 
solution. However, most of the time, it serves as a bridging 
therapy before elective LC.
Managing AC is a multidisciplinary task which aims to 
treat the disease most effectively by avoiding septic complica-
tions. In many cases, despite the detailed recommendations in 
the guidelines, it is difficult to decide which treatment strategy 
is the most ideal for the patient. Nevertheless, whatever treat-
ment or path we choose, the objective is to avoid complications 
and decrease mortality and thus to increase survival.
The success of AC treatment may be influenced by sev-
eral factors, such as general condition, comorbidities, patient 
age and level of gallbladder inflammation. The aim of this 
study is to ascertain how these factors influence the success 
of PTGBD, the timing of subsequent cholecystectomies and 
their outcomes. In addition, it is necessary to further clarify 
the role and place of PTGBD in the complex treatment algo-
rithm of AC.
Materials and methods
Ethical permission (81/2020-SZTE) for the study was 
obtained from the Regional Human Biomedical Research 
Ethics Committee of the University of Szeged.
We retrospectively examined abdominal ultrasound (US)-
guided PTGBD interventions performed with AC indication 
at the University of Szeged for a ten-year period from 2010 
to 2020. Patients who underwent percutaneous transhepatic 
gallbladder aspiration or endosonography-guided gallblad-
der drainage or computer tomography (CT)-guided PTGBD 
were excluded from the study. We did these exclusions to 
provide a homogenous study population in terms of the 
used interventional radiology method (i.e. only ultrasound-
guided PTGBD). Moreover, nine patients who had a history 
of hepato-pancreatic-biliary malignancy prior to PTGBD or 
who were diagnosed with it after the procedure as well as 
patients who received further treatment after PTGBD out-
side the University of Szeged were excluded. After exclu-
sions, data were analysed from 162 patients with PTGBD.
In radiologically confirmed AC patients, the TG13 and 
TG18 recommendations were followed when indicating 
PTGBD [18, 12, 11].
The severity of inflammation was determined retrospec-
tively based on the TG18/TG13 severity grading for acute 
cholecystitis defined in the Tokyo Guidelines 2018 [19]. The 
severity of AC-related inflammation in each patient was clas-
sified as grade I (mild), II (moderate) and III (severe). Based 
on abdominal ultrasound, the indications for PTGBD were 
grouped as follows: acute acalculous cholecystitis (AAC), 
acute calculous cholecystitis (ACC), empyema vesicae 
felleae (EVF), hydrops vesicae felleae (HVF) and covered 
perforated cholecystitis (PC) [20].
Sex and age group (18–65 years or over 65 years) distri-
bution and patient’s performance status were determined: 
the ASA score (I–VI) was determined for each patient, and 
patients were classified into three groups based on the Charl-
son comorbidity index (CCI) as follows: CCI 0, CCI 1–3 and 
over CCI 4. Based on the time elapsed between the onset of 
complaints and PTGBD, patients were grouped into three 
categories (0–72 h, three days to one week and beyond one 
week).
The average duration of drain presence after PTGBD 
was assessed. The need for endoscopic retrograde cholan-
giopancreatography (ERCP) during hospitalization and after 
hospital discharge time over an average were followed for a 
five-year period. The indications of ERCP (non-decreasing 
biliary excretion, sepsis (including cholangiosepsis), biliary 
obstruction (BO)) and its results were assessed. The need for 
urgent CCY due to the rapidly deteriorating clinical condi-
tion of the patients after PTGBD was determined.
Three endpoints were determined in terms of clinical 
and surgical outcomes of PTGBD. The clinical success rate 
(CSR) of PTGBD (number of clinically regressive cases 
after PTGBD X 100/[total number of PTGBD procedures 
– number of technically unsuccessful procedures]) was cal-
culated. Clinical regression was determined by remission of 
patient’s symptoms, improvement in inflammatory markers 
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(leukocyte count, CRP and PCT) and radiological (US or 
abdominal CT) regression. As a routine practice, we fol-
lowed up the patients with control abdominal ultrasound 
after the PTGBD everyday/every second day or rarely with 
CT. We check the position of the inserted tube/drain and 
the possible regression or progression of the gall bladder 
inflammation (thickness of the gallbladder wall, perichol-
ecystic fluid, etc.).
CSR was assessed according to different patient sexes, 
age groups, TG18/13 AC severity grades, CCI and time 
elapsed between the onset of complaints and hospital admis-
sion were analysed.
In addition to CSR, the technical success rate (TSR) 
of PTGBD (technically successful procedure × 100/total 
procedures) was also calculated. We interpreted invasive 
radiological interventions where we observed drain failure 
(occlusion, drain displacement, improper tube positioning, 
etc.) as technically unsuccessful PTGBD.
As a second endpoint in terms of clinical outcome, we 
analysed the proportion of CCYs after PTGBD and the need 
for possible emergency surgeries. We examined the propor-
tion of PTGBD reported as final therapy (no need for CCY) 
and as a bridging therapy (i.e. the percentage of elective 
CCY performed in patients who responded well to drain-
age). All elective CCY surgeries performed after hospital 
discharge during an average five-year follow-up period were 
analysed. In terms of surgical outcome, we determined the 
proportion of primary open cholecystectomy, laparoscopic 
cholecystectomy (LC) and conversion after LC during both 
emergency and elective CCY surgery. Based on the above, 
the conversion rate (CR) of LCs (number of converted LCs 
× 100/[number of total surgeries – number of primary open 
cholecystectomies] and the laparoscopic success rate (LSR) 
(number of LCs/numbers of total surgeries) were calculated. 
Elective surgeries were further divided into two groups 
according to the time elapsed between PTGBD and the CCY 
surgery (performed between three to six weeks and after six 
weeks). In these groups, the previous parameters (CR and 
LSR) were also determined. Possible bile duct injury during 
CCY was examined as well.
Finally, as a third endpoint in terms of clinical and sur-
gical outcome, we calculated the in-hospital mortality and 
procedure mortality (directly related to PTGBD, such as 
bleeding, embolism and other organ injury). We further ana-
lysed in-hospital mortality in relation to different patient or 
intervention characteristics.
Statistical analysis
Detailed descriptive statistics for continuous and categorical 
variables were reported. Welch’s t-test, one-way ANOVA, 
Pearson’s chi-squared test or Fischer’s exact test were used 
for the univariate analysis, as appropriate. We tested the 
association between negative patient outcomes (in-hospital 
mortality, clinical progression and emergency cholecystec-
tomy) and patient’s performance status or ACC severity with 
a univariate method followed by logistic regression. Statisti-
cal analysis was performed using R 3.5.1.
Results
Among the 162 patients who underwent PTGBD within 
the ten-year investigation period, there were nearly equal 
proportions of men and women (51.23% vs. 48.77%). Their 
mean age was 71.43 ± 13.22 years, and the majority of them 
(71.60%) was over 65 years of age. It should be noted that 
the age of patients who died after PTGBD during in-hospi-
tal time was significantly higher compared to the survival 
group (76.82 ± 9.77 vs. 71.16 ± 12.98 years). Mean age was 
significantly higher in more severe inflammation (grade I: 
63.14 ± 16.52 years; grade II: 70.79 ± 13.14 years; grade III: 
78.89 ± 7.22 years) and in patients who required emergency 
CCY than those who had elective CCY (74.75 ± 13.13 vs. 
68.00 ± 11.05 years). In cases where no surgical procedure 
was performed, PTGBD served as definitive therapy. Mean 
age of these patients was 73.39 ± 15.39 years.
In addition to the high mean age, the majority of the 
PTGBD patients had a CCI above 4 (65.38%). The distribu-
tion of the AC severity grade was the following: grade I: 
8.8%; grade II: 73.6%; and grade III: 17.6. Most frequently, 
PTGBD was called for due to abdominal US-confirmed 
ACC in 33.95% of the cases, covered cholecystitis perfo-
ration in 27.16% and AAC in 5.56% (Table 1). Hospital 
admission occurred between 72 h and one week after the 
onset of complaints in almost half of the cases (45.6%). In 
general, PTGBD was performed within 72 h in 39.71% of 
the cases, and beyond one week in 14.71%. TSR for PTGBD 
was 97.53%, procedure mortality was 0%, and CSR was 
87.97%. The drain inserted was removed 11.65 ± 7.57 days 
after PTGBD on average. After PTGBD, 62 (42.18%) did 
not undergo subsequent CCY; drainage therefore proved to 
be a definitive therapy. 69 patients (46.94) had CCY, and 16 
patients (10.88%) had emergency surgery due to the deterio-
rating clinical condition and progression. The mean timing 
of elective surgeries was 13.57 ± 10.89 weeks after PTGBD 
(Table 1).
CSR of PTGBD deteriorated significantly in patients 
over 65 years and in parallel with the increasing severity 
of the inflammation (Table 2). While basically all patients 
under 65 years of age experienced clinical regression, 
CSR was only 83.62% in patients over 65 years. In grade 
I inflammation, we also had complete clinical success 
in all patients; however, CRS was 92.04 in grade II and 
only 64.29% in grade III. The clinical regression varied 
inversely with the ASA score and a similar tendency could 
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Table 1  General patient and intervention characteristics
AC Acute cholecystitis, AAC Acute acalculous cholecystitis, ACC Acute calculous cholecystitis, BDI Bile duct injury, CCY Cholecystectomy, 
CSR Clinical success rate, ERCP Endoscopic retrograde cholangiopancreatography, EVF Empyema vesicae felleae, HVF Hydrops vesicae 
felleae, NA No data, PC Covered perforated cholecyst, TSR Technical success rate, TG13/18 Tokyo Guidelines 2013 and 2018, US Ultrasound
N % Mean ± SD Min–Max
Age (years) 30–65 46 28.4
65 + 116 71.6
Total 162 100 71.43 ± 13.22 33–95
Sex Female 79 48.77
Male 83 51.23
Total 162 100





CCI CCI 0 8 5.13
CCI 1–3 46 29.49
CCI 4 + 102 65.38
Total 156 100 4.21 ± 2.25 0–10
NA 6
Time frame (between onset of complaints and hospital admission) 0–72 h 54 39.71
72 h–1 week 62 45.59
Over 1 week 20 14.71
NA 26









PTGBD TSR N = 162 100% 97.53
PTGBD CSR N = 162 100% 87.97
Time of drain removal after PTGBD (days) 88 11.65 ± 7.57 1–42
NA 76
Mortality after PTGBD Procedure mortality 0 0
In-hospital mortality 17 11.72
ERCP after PTGBD During hospital stay 21 13.46
After hospital discharge 4 2.56
There was no ERCP 131 83.97
NA 6
CCY after PTGBD Emergency CCY 16 10.88
Elective CCY 69 46.94
There was no surgery 62 42.18
BDI during CCY after PTGBD 1 1.17
Time interval between PTGBD and CCY Emergency (days) 16 19.05 5.50 ± 12.56 0–52
Elective (weeks) 68 80.95 13.57 ± 10.89 2–67




be observed for CCI; CSR was 100% for CCI 0, 88.37% for 
CCI 1–3 and 86.96% for CCI 4 + . There was no significant 
difference in CSR in relation to time elapsed between the 
onset of complaints and hospital admission (see Table 3).
After PTGBD, ERCP was necessary in 15.43% of the 
cases (25 cases) (Table 2). The most common indication 
for ERCP was in cases, where no reduction in bile flow 
through the inserted gallbladder drain was seen. Irrespec-
tive of the indication for ERCP, choledocholithiasis was 
confirmed in 40% of the cases (Table 2).
Comparing emergency and elective CCY surgeries after 
PTGBD in terms of LSR and CR (Table 4), the proportion 
of primary open cholecystectomies in elective surgeries 
was much lower (5/16 (7.24%) vs. 5/69 (31.25%)). The CR 
of elective LCs (17.46%) was similar to that of emergency 
LCs (18.18%).
If we further analyse elective and emergency CCYs 
(Table  5), it can be seen that emergency CCYs were 
mainly performed in older patients with higher CCI or 
more severe AC.
In addition to the 0% procedure mortality directly asso-
ciated with the PTGBD intervention, in-hospital mortality 
was 11.72% (Table 6). There was no significant differ-
ence in mortality between male and female patients; how-
ever, mortality showed a corresponding increase with the 
increasing score for both ASA score and CCI. The most 
prominent mortality was observed in AAC cases. In this 
scenario, five out of nine patients died with an in-hospital 
mortality of 55.56%, while mortality was only 6.00% for 
ACC. Mortality after elective surgery was 0%; however, 
if emergency CCY was required after PTGBD, we lost 
14.29% of the patients.
The logistic regression (Table 7) showed that the sever-
ity of AC inflammation had the highest odds for emergency 
CCY (OR 14.75; CI 3.07–70.81). The degree of inflamma-
tion also had a significant effect on clinical progression (OR 
7.62; Cl 2.64–22.05) and on in-hospital mortality (OR 6.07; 
CI 1.79–20.56). CCI had a significant odds ratio only for in-
hospital mortality (similarly to the results of the univariate 
analysis).
Discussion
Therapy of AC is a complex multidisciplinary task. A num-
ber of factors must be considered to make a therapeutic 
decision. According to the Tokyo Guidelines 2018 recom-
mendations, we should consider the patient’s age, general 
condition, comorbidities, the beginning of his or her com-
plaints and the severity of the gallbladder inflammation [11].
US-guided PTGBD has been used for almost four dec-
ades and nowadays plays an important role in emergency 
care for AC [1, 3, 4, 2, 21]. PTGBD is a relatively easy 
procedure with a high technical success rate, used mainly in 
moderate-to-severe AC if the patient is not fit for surgery or 
does not respond adequately to antibiotics and general sup-
portive care [8]. Although a patient’s advanced age is not an 
absolute contraindication for acute early CCY, it may still 
be a determinant of complex AC treatment success [22]. Our 
study showed that PTGBD was mainly performed in older 
Table 2  Indications and timing 
of endoscopic retrograde 
cholangiopancreatography 
(ERCP) after percutaneous 
transhepatic gallbladder 
drainage (PTGBD)
BDI Bile duct injury, BO Biliary obstruction, CBDS Common bile duct stone, NA No data, SOD Sphincter 
of Oddi dysfunction
ERCP indication ERCP outcome N
During in-hospital stay
N = 20; 83.33%
Non-decreasing biliary excretion
N = 12; 50.00%
BO: CBDS 5
BO: Juxtapapillary diverticulum 2
BO: SOD 2
BO: Sclerosis of Vater’s papilla 1
Irregular pancreatic anatomy 1
BO: Mirizzi syndrome 1
Cholangiosepsis
N = 4; 16.66%
BO: CBDS 2
BO: Duodenal stenosis 1
BO: Biliary stent obstruction 1
Increased biliary obstruction enzymes
N = 3; 12.50%
BO: Juxtapapillary diverticulum 2
BO: CBDS 1
Sepsis Abdominal gallbladder perforation 1
After hospital discharge
N = 4; 16.67%
Increased biliary obstruction enzymes BO: CBDS 2
Cholangiosepsis BO: CBDS 1





patients (mean age: 71.43 ± 13.22 years) with AC and CSR, 
with 83.62% of the patients being over 65 years. Higher 
mean age was also observed in more severe inflammation. 
Consequently, it is likely that the less elderly age group is 
more likely to experience clinical regression, while CSR is 
literally 100% for patients under 65 years.
Based on our findings, grade II and grade III inflamma-
tion mainly occurred in older patients. Among a popula-
tion with advanced age, a higher CCI may accompany a 
potentially increased mortality rate. In our study, in-hospital 
mortality was 15.96% in CCI 4 + patients and 0% in CCI 
0–3. Based on previous reports, AC mortality varied with 
the severity of the inflammation. While 30-day mortality was 
1.1% in mild inflammation (grade I), it was 0.8% in moderate 
(grade II) and 5.4% in severe inflammation [23]. In-hospi-
tal mortality after PTGBD was relatively high (11.72%) in 
our study. High mortality after PTGBD was confirmed by 
a systematic review conducted by Winbladh et al., which 
showed 15.4% total mortality (30-day mortality or in-
hospital death) [8]. Dimou et al. reported 24% in-hospital 
Table 3  Technical success rate and clinical outcomes of percutaneous transhepatic gallbladder drainage (PTGBD) according to patient charac-
teristics










Total TSR % CSR % p*
Total 19 139 4 162 97.53 87.97
Age (years) 30–65 0 42 4 46 100 0.003926
65 + 19 97 0 116 83.62
Sex Female 11 65 3 79 85.53 0.5053
Male 8 74 1 83 90.24
ASA score 1 0 14 2 16 100 –
2 12 52 1 65 81.25
3 4 49 1 54 92.45
4 3 20 0 23 86.96
NA 4 4
CCI CCI = 0 0 7 1 8 100 0.6372
CCI = 1–3 5 38 3 46 88.37
CCI = 4 + 14 88 0 102 86.27
NA 6 6
Time frame (between onset of 
complaints and hospital admis-
sion)
0–72 h 8 46 0 54 85.19 0.8191
72 h–1 week 7 52 3 62 88.14
Over 1 week 2 17 1 20 89.47
NA 2 24 26
AC severity grade (TG18/TG13) I 0 14 0 14 100 0.0009995
II 9 104 4 117 92.04
III 10 18 0 28 64.29
NA 3 3
Table 4  Characteristics of cholecystectomies (CCY) performed after percutaneous transhepatic gallbladder drainage (PTGBD)
LSR Laparoscopic success rate (number of LCs/total number of surgeries), CR Conversion rate (number of converted LCs × 100/[total number 
of surgeries – number of primary open cholecystectomies]) (*Fischer’s Exact Test)
LC Converted LC Primary 
open CCY 
NA Total LSR (%) p* LSR% CR (%)
Total 61 13 10 1 85 71.76 – 17.57
CCY after PTGBD Emergency 9 2 5 16 56.25 0.1367 18.18
Planned CCY 52 11 5 1 69 75.36 17.46
within 3 to 6 weeks 5 1 1 8 62.50 0.3969 16.67
after 6 weeks 47 10 4 61 77.05 17.54
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mortality after 563 PTGBDs [24]. Although the guidelines 
recommend PTGBD for elderly or critically ill patients as 
well as in grade II–III inflammation [22, 11], mortality of 
approximately 41% was observed in grade III inflammation 
after PTGBD in this study. Based on logistic regression, the 
severity of inflammation was the most significant factor in 
patient survival. It should be noted that Sanaiha et al. found 
significantly lower mortality in grade III inflammation after 
early LC than in percutaneous cholecystostomy based on a 
retrospective cohort of 358,624 patients [25]. This further 
elucidates the role of PTGBD as well as acute or early LC 
in the complex treatment of grade III AC.
In addition to mortality, the success of PTGBD is demon-
strated by the need for emergency CCY, among other treat-
ment options. In a systematic review by Winbladh et al., the 
frequency of emergency CCY after percutaneous cholecys-
tostomy was found to be between 2% and 20% [8]. In our 
study, emergency CCY was performed in 10% of the cases. 
These surgeries may become necessary when the disease 
progresses despite PTGBD and antibiotics or general sup-
portive treatment. In the case noted above, extremely dif-
ficult surgeries can be expected with a high rate of primary 
open cholecystectomies (31.25%) and CR (18.18%), based 
on our study. The purpose of timely emergency CCY sur-
geries is to avoid complications, sepsis and septic shock as 
much as possible. We have to consider the fact that there is 
clinical progression after PTGBD in some cases and thus 
emergency CCY surgery should be performed (9.87%), 
which is a critical situation with high overall mortality 
(14.29%). In view of these results, the choice of emergency 
CCY or PTGBD should be considered in AC with grade III 
inflammation.
Several studies recommend percutaneous cholecysto-
stomy in AAC [26, 27]. We should highlight that almost 
56% mortality was observed after PTGBD among patients 
with AAC in our study. Due to the low number of cases, we 
Table 5  The characteristics of emergency and elective cholecystectomies (CCY) performed after percutaneous transhepatic gallbladder drainage 
(PTGBD)
AC Acute cholecystitis, AAC Acute acalculous cholecystitis, ACC Acute calculous cholecystitis, EVF Empyema vesicae felleae, HVF Hydrops 







N = 69 (100%) N = 16 (100%)
Age (years) 30–65 27 (39.13%) 2 (12.5%) 29 p value = 0.0762 Fisher’s exact test
65 + 42 (60.87%) 14 (87.5%) 56
Sex Female 29 (42.03%) 10 (62.5%) 39 p value = 0.1698 Fisher’s exact test
Male 40 (57.97%) 6 (37.5%) 46
ASA score 1 6 (8.7%) 2 (12.5%) 8 p value = 0.7576 Pearson’s chi-squared test 
with simulated p value (based on 2000 
replicates)
2 37 (53.62%) 10 (62.5%) 47
3 23 (33.33%) 3 (18.75%) 26
4 3 (4.35%) 1 (6.25%) 4
CCI CCI = 0 3 (4.41%) 1 (6.25%) 4 p value = 0.8236 Pearson’s chi-squared test 
with simulated p value (based on 2000 
replicates)
CCI = 1–3 29 (42.65%) 5 (31.25%) 34
CCI = 4 or 4 + 36 (52.94%) 10 (62.5%) 46
NA 1 1
Time frame (between onset of complaints 
and hospital admission)
0–72 h 23 (36.51%) 6 (42.86%) 29 p value = 0.93
Pearson’s chi-squared test with simulated p 
value (based on 2000 replicates)
72 h–1 week 30 (47.62%) 6 (42.86%) 36
Over 1 week 10 (15.87%) 2 (14.29%) 12
NA 6 2 8
Indication of PTGBD based on abdomi-
nal US
AAC 2 (2.9%) 1 (6.25%) 3 p value = 0.7836 Pearson’s chi-squared test 
with simulated p value (based on 2000 
replicates)
ACC 25 (36.23%) 8 (50%) 33
EVF 5 (7.25%) 1 (6.25%) 6
HVF 16 (23.19%) 2 (12.5%) 18
PC 21 (30.43%) 4 (25%) 25
AC severity grade (TG18/TG13) I 9 (13.04%) 0 (0%) 9 p value = 0.0004998
II 56 (81.16%) 9 (56.25%) 65 Pearson’s chi-squared test with simulated p 
value (based on 2000 replicates)
III 4 (5.8%) 7 (43.75%) 11
 Surgical Endoscopy
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Table 6  Survival and in-hospital mortality according to patient and intervention characteristics
AAC Acute acalculous cholecystitis, ACC Acute calculous cholecystitis, EVF Empyema vesicae felleae, HVF Hydrops vesicae felleae, NA No 
data, PC Covered perforated cholecyst, PTGBD Percutaneous transhepatic gallbladder drainage, TG13/18 Tokyo Guidelines 2013 and 2018, US 
Ultrasound (*Fischer’s exact test and Pearson’s chi-squared test)
Total N Survival In-hospital mortality NA p
162 128 (88.28%) 17 (11.72%) 17 –
Age (years) 30–65 46 36 (90.00%) 4 (10.00%) 6 0.7811
65 + 116 92 (87.62%) 13 (12.38%) 11
Sex Female 79 58 (87.88%) 8 (12.12%) 13 1
Male 83 70 (88.61%) 9 (11.39%) 4
ASA score 1 16 15 (100.00%) 0 (0.00%) 1 sim p value = 0.001999
2 65 55 (98.21%) 1 (1.79%) 9
3 54 42 (85.71%) 7 (14.29%) 5
4 23 15 (68.18%) 7 (31.82%) 1
CCI CCI = 0 8 6 (100.00%) 0 (0.00%) 2 sim p value = 0.02299
CCI = 1–3 46 41 (100.00%) 0 (0.00%) 5
CCI = 4 + 102 79 (84.04%) 15 (15.96%) 8
NA 6
Time frame (between onset of complaints 
and hospital admission)
0–72 h 54 46 (86.79%) 7 (13.21%) 1 sim p value = 0.1729
3 days–1 week 62 52 (96.3%) 2 (3.70%) 3
Over 1 week 20 15 (88.24%) 2 (11.76%) 8
NA 26
Indication of PTGBD based on abdominal 
US
AAC 9 4 (44.44%) 5 (55.56%) 0 —
ACC 55 47 (94.00%) 3 (6.00%) 5
EVF 17 11 (91.67%) 1 (8.33%) 5
HVF 37 30 (88.24%) 4 (11.76%) 3
PC 44 36 (90.00%) 4 (10.00%) 4
AC severity grade (TG18/TG13) I 14 14 (100%) 0 (0%) 0 sim p value = 0.0004998
II 117 100 (92.59%) 8 (7.41%) 9
III 28 13 (59.09%) 9 (40.91%) 6
NA 3
CCY after PTGBD Planned 69 66 (100%) 0 (0%) 3 0.0288
Emergency 16 12 (85.71%) 2 (14.29%) 2
Table 7  Logistic regression between negative patient outcomes (in-hospital mortality, clinical progression and emergency cholecystectomy) and 
patient’s performance status or AC severity
AC Acute cholecystitis, B Regression coefficient, CCI Charlson comorbidity index, df Degree of freedom, OR Odds ratio, CI Confidence interval
B S.E df P OR (95% CI) Model characteristics
In-hospital mortality N = 141 CCI 0.562 0.168 1 0.001 1.75 (1.26–2.44) Nagelkerke R-squared = 0.345; 
Correct predictions = 87.2%AC severity grade 1.803 0.623 1 0.004 6.07 (1.79–20.56)
Constant −9.154 1.955 1 0.000
Clinical progression after PTGBD 
N = 152
CCI −0.001 0.136 1 0.995 1.00 (0.77–1.3) Nagelkerke R-squared = 0.199; 
Correct predictions = 87.5%AC severity grade 2.031 0.542 1 0.000 7.62 (2.64–22.05)
Constant −6.533 1.287 1 0.000
Emergency CCY after PTGBD
N = 84
CCI −0.124 0.182 1 0.495 0.88 (0.62–1.26) Nagelkerke R-squared = 0.273; 
Correct predictions = 84.5%AC severity grade 2.691 0.800 1 0.001 14.75 (3.07–70.81)
Constant −6.812 1.611 1 0.000
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have to interpret these results cautiously. However, a similar 
tendency was reported by Winbladh and his colleagues. In 
diagnostically uncertain cholecystitis, mortality was signifi-
cantly higher than in AC with a clear origin; where the rate 
of gallstones was lower, mortality was expected to be higher, 
even up to 40–60% [8]. The previous observation was sup-
ported by a population-based analysis by Schlottmann et al. 
[28], in which a significantly worse postoperative outcome 
was observed in AAC than in patients with ACC after 7,516 
cholecystostomy tube placement interventions.
Focussing on the proportion of elective cholecystecto-
mies, it appears that cholecystectomy (CCY) was not per-
formed after PTGBD in almost half of the cases (46.94%). 
Harai and his colleagues reported a similar trend: no CCY 
surgery was performed in almost 40% of cases after PTGBD 
[29]. Moreover, in a systematic review study of 1,925 
patients by Winbladh and his colleagues, the proportion of 
patients who did not undergo surgery after percutaneous 
cholecystostomy was 62% [8]. PTGBD can be considered as 
a definitive final therapy [30]. This is also confirmed by our 
results, which showed that elective LCs generally occurred 
in younger patients (68.35 ± 11.34  years) compared to 
patients without further elective CCY (73.39 ± 15.39 years). 
Clarification of the causes of non-occurring CCY requires 
further investigation.
Emergency or urgent surgeries were needed in clinical 
progression and when the patient did not respond well to 
PTGBD intervention, especially in older patients with poor 
general condition (with high CCI) diagnosed with severe 
AC. Based on logistic regression analyses, the level of gall-
bladder inflammation has been significantly associated with 
the need for urgent surgery after PTGBD.
In the CRs of surgeries performed with different timings 
(elective or emergency), there was essentially no difference 
(17.46% vs. 18.18%). A similar result was obtained by Ni 
and colleagues [31], who found a conversion rate of 19.2% 
in patients who had previously undergone PTGBD. On aver-
age, the CR is around 4% during elective LCs [32, 33], but 
the CR of acute LC was around 9–10%. The remarkably 
high CR of elective LCs after PTGBD may be explained by 
the fact that these delayed LC surgeries were performed in 
older patients (68.35 ± 11.34 years), where, in addition to 
age, gallbladder wall thickening and adhesions from previ-
ous inflammation may further increase the chance of con-
version. In these cases, it can be very difficult to accurately 
identify the structures of the Calot triangle that may lead to 
biliary tract injury. The ratio of major, Strasberg type D bile 
duct injury may be as high as 9.5% [34, 35]. In our study, 
the BDI ratio during CCY after PTGBD was 1.17%, which 
is roughly the same as the results reported by Altieri and 
her colleagues in 2019. According to Altieri, elective CCYs 
occurred in approximately 30% of patients after 9,738 PTG-
BDs, with a BDI rate of approximately 1.6% [36].
Following PTGBD, a relatively high portion (approxi-
mately 15% of patients) required ERCP. According to the 
literature, the need for ERCP can reach as high as 40% [37, 
38]. In our study, ERCP was most often indicated due to 
the non-decreasing amount of bile excreted through the 
inserted drain. In most of the cases, the result of ERCP was 
biliary obstruction BO, including choledocholithiasis. We 
hypothesize that common bile duct stone (CBDS) played an 
important role in the development of AC in most patients, as 
AC more easily develops by increasing biliary pressure and 
interfering with gallbladder emptying. Based on our study, 
CBDS caused a problem indicating ERCP in approximately 
44% of patients who underwent PTGBD. The importance 
of CBGS has been highlighted in several reports, including 
Kuan and her colleagues, who reported a 7–27% incidence 
of CBDS following percutaneous cholecystostomy [37, 
38]. In mild or complete biliary obstruction, bile is emptied 
through a drain inserted into the gallbladder due to increased 
biliary pressure, which in many cases prevents the drain 
from being removed. Another cause of heavy bile excretion 
may be minor bile duct injury during a PTGBD procedure; 
however, no such case was observed in our study. In the light 
of this, it is recommended that ERCP be performed in cases 
where biliary excretion does not decrease after PTGBD.
Conclusion
PTGBD is an easy-to-perform intervention in the treatment 
of acute cholecystitis with good TSR, with clinical and 
surgical success influenced by several factors, such as the 
patient’s age and the level of gallbladder inflammation. It 
is used as a definitive therapy in a significant proportion of 
patients, while it serves as bridging for other patients before 
subsequent elective CCY. The level of inflammation plays a 
crucial role in the course of AC, whereas in severe, grade III 
inflammation, we have to consider high clinical progression, 
a high proportion of emergency CCYs and high mortality 
after PTGBD.
Limitations of the study
Limitations include retrospective nature of the study, with 
relative restrictions in patient selection and inclusion. We 
were unable to identify patients who had died outside our 
institutions; therefore, we could not determine the exact 
number and causes of the 30-day and overall mortality. After 
PTGBD, we were unable to identify the direct causes of the 
absence of elective CCY, so we can only infer them.
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